Emerging viral diseases and infectious disease risks

New pathogens and antimicrobial-resistant forms of older pathogens continue to emerge, some with the potential for rapid, global spread and high morbidity and mortality. Pathogens can emerge either through introduction into a new population or when the interaction with the vector changes; emergence is also influenced by microbiological adaptation and change, global travel patterns, domestic […]

HUMAN IMMUNODEFICIENCY VIRUS, HEPATITIS C VIRUS AND HEPATITIS B VIRUS INCIDENCE IN BLOOD DONORS FROM 2000 TO 2020 IN FRANCE: TRENDS AND LESSONS FROM HAEMOVIGILANCE SURVEILLANCE

Data from 21 years (2000–2020) of haemovigilance were used to assess human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) incidence rates in repeat blood donors and the occurrence of transfusion-transmitted (TT) viral infections. Blood donors who converted for HIV, HCV or HBV markers within serial three-year analysis periods were included. Epidemiological […]

Epidemiological characteristics of human prion diseases

In the absence of specific therapies for human prion diseases, which are frequently associated with neurodegenerative disorders with fatal outcome, only an active surveillance can be used to monitor and prevent the transmission of such diseases. For this reason, starting from 1993, surveillance systems have been established in many countries. Moreover, there is urgent need […]

Intracranial Haemorrhage in Haemophilia Patients Is Still an Open Issue: The Final Results of the Italian EMO.REC Registry

Abstract: Background: Intracranial hemorrhage (ICH) is a highly serious event in patients with haemophilia (PWH) which leads to disability and in some cases to death. ICH occurs among all ages but is particularly frequent in newborns. Aim: The primary aim was to assess the incidence and mortality due to ICH in an Italian population of […]

Delivery of gene therapy in haemophilia treatment centres in the United States: Practical aspects of preparedness and implementation

Haemophilia treatment centres (HTCs) and healthcare providers (HCPs) will need to adapt to a new treatment paradigm with the emergence of adeno-associated virus (AAV)-based gene therapy for the treatment of haemophilia in adults. Aim: This review examines the upcoming patient and institutional journeys, along with practical aspects of preparedness for clinical delivery of gene therapy by […]

Hemophilia: an emergency

Hemophilia and Sport: achievable goals

Unmet needs in Moderate and Mild Hemophilia

The functions of Coagulation Factor VIII